Cover Image
市場調查報告書

Arena Pharmaceuticals, Inc.:產品平台分析

Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224643
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Arena Pharmaceuticals, Inc.:產品平台分析 Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月20日 內容資訊: 英文 48 Pages
簡介

Arena Pharmaceuticals, Inc.是研究、開發及商品化針對肥胖症、糖尿病、肺動脈高血壓(PAH)、血栓性疾病、自體免疫疾病、疼痛管理等治療藥的生物醫藥品企業。

本報告提供Arena Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Arena Pharmaceuticals, Inc.的基本資料

Arena Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Arena Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Arena Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Arena Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

Arena Pharmaceuticals, Inc.:藥物簡介

  • APD-334
  • APD-371
  • APD-668
  • APD-811
  • temanogrel hydrochloride
  • APD-597

Arena Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Arena Pharmaceuticals, Inc.:最近的開發平台趨勢

Arena Pharmaceuticals, Inc.:暫停中的計劃

Arena Pharmaceuticals, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
  • APD-597
  • nelotanserin

Arena Pharmaceuticals, Inc.:企業發表

Arena Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07064CDB

Summary

Global Markets Direct's, 'Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Arena Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Arena Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Arena Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Arena Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Arena Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Arena Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Arena Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Arena Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Arena Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arena Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Arena Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Arena Pharmaceuticals, Inc. Snapshot
    • Arena Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Arena Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Arena Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Arena Pharmaceuticals, Inc. - Pipeline Products Glance
    • Arena Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
    • Arena Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Arena Pharmaceuticals, Inc. - Drug Profiles
    • lorcaserin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ralinepag
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APD-334
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APD-371
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • temanogrel hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arena Pharmaceuticals, Inc. - Pipeline Analysis
    • Arena Pharmaceuticals, Inc. - Pipeline Products by Target
    • Arena Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Arena Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Arena Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Arena Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Arena Pharmaceuticals, Inc. - Dormant Projects
  • Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • APD-597
      • nelotanserin
  • Arena Pharmaceuticals, Inc. - Company Statement
  • Arena Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Arena Pharmaceuticals, Inc., Key Information
  • Arena Pharmaceuticals, Inc., Key Facts
  • Arena Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Arena Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Arena Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Arena Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Arena Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Arena Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Arena Pharmaceuticals, Inc. - Pre-Registration, 2015
  • Arena Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2015
  • Arena Pharmaceuticals, Inc. - Phase II, 2015
  • Arena Pharmaceuticals, Inc. - Phase I, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Arena Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Arena Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Arena Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Arena Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Arena Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Arena Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top